Study period 1/1/2017 to 7/1/2025 Study population: inclusion Patients with A GLP-1 prescription for at least 90 days At least five pounds of weight loss while on the GLP-1 A weight reading between 30 days prior through 3 days after starting the GLP-1 A weight reading within 30 days of stopping the GLP-1 At least one weight reading 1 to 24 months following end of the GLP-1 Study population: exclusion Thyroid conditions (ever): ICD-10-CM E03*or E05* Eating disorders (ever): ICD-10-CM F50* Pregnancy within a year before GLP-1 start through GLP-1 stop Censoring Other weight loss medication or restart of GLP-1 Amputation Bariatric surgery Pregnancy that started in period after GLP-1 was stopped Outcomes Percent of weight change relative to initial weight loss after end of GLP-1 treatment GLP-1 A medication with a simple generic of semaglutide, liraglutide, or tirzepatide

Injection Site Reactions For subcutaneous formulations, mild injection site reactions including redness, itching, swelling, or bruising occur occasionally
In the case of BPC-157, this raises a thorny set of questions: In a world of hype and financial conflicts of interest, how informed can patients be
These products may be manufactured under murky circumstances, often overseas, so theres no way of knowing what could be in them
At Injex Clinics, weve been delivering high-quality cosmetic treatments
Our MD specialists will discuss realistic outcomes based on your unique skin profile during your consultation at our Hyderabad clinic